{
    "clinical_study": {
        "@rank": "28412", 
        "arm_group": {
            "arm_group_label": "5-AminoLevulinicc Acid", 
            "arm_group_type": "Experimental", 
            "description": "consists of 60mg/kg 5-ALA prepared solution given orally, 3-5 hours before induction of anesthesia and surgical tumor resection. Red light laser given by a Dye laser system, wave length of 635nm, in s dose of 150J/cm for 2000 seconds (33 minutes) will be given to tumor bed. In the case of positive margins (for tumor presence), a second surgical intervention followed by second 60mg/kg 5-ALA administration will be performed."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to  evaluate the efficacy of preoperative 5-ALA oral\n      administration and subsequently intraoperative tumor bed phototherapy with red light laser,\n      as an adjuvant therapy on the 3 years rate of local tumor recurrence in patients with\n      desmoid tumors. To evaluate the Safety of 5-ALA administration. 5 years local recurrence\n      rate."
        }, 
        "brief_title": "Safety and Efficacy Study Using 5-ALA Oral Administration as an Adjuvant Therapy on the Rate of Local Tumor Recurrence in Patients Who Have Desmoids Tumors", 
        "completion_date": {
            "#text": "December 2026", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "The Aim of the Study is to Evaluate the Efficacy of Photodynamic Therapy as an", 
            "Adjuvant Therapy on the Clinical Outcome of Patients With Desmoid Tumors After", 
            "Surgical Resection"
        ], 
        "condition_browse": {
            "mesh_term": "Fibromatosis, Aggressive"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patient has a resectable histologically confirmed desmoid tumor.\n\n          2. Previously treated (by chemotherapy, irradiation or surgery) patients are eligible.\n\n          3. Age > 18 years\n\n          4. Signed informed consent prior to patient recruitment. -\n\n        Exclusion Criteria:\n\n          1. Hepatic enzymes or bilirubin > 2X upper limit of normal.\n\n          2. Serum creatinine > 2.5 x upper limit of normal.\n\n          3. Suspected /documented metastatic disease.\n\n          4. Active or uncontrolled infections.\n\n          5. Active second malignant disease (excluding non-melanoma skin cancer, or in situ\n             cervix or breast carcinoma) < 2 years prior to the study.\n\n          6. Use of other investigational agents < 30 days prior to the study.\n\n          7. Patients who are mentally or physically unable to comply with all aspects of the\n             study.\n\n          8. Any serious medical condition, including the presence of laboratory abnormalities,\n             which places the subject at an unacceptable risk if he or she participates in this\n             study or confounds the experimental ability to interpret data from the study.\n\n          9. Pregnant or lactating females.\n\n         10. Known intolerance or allergy to 5-ALA\n\n         11. Suspicious or documented acute or chronic porphyria"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "140", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01898416", 
            "org_study_id": "TASMC-11-JB-558-CTIL"
        }, 
        "intervention": {
            "arm_group_label": "5-AminoLevulinicc Acid", 
            "description": "60 mg/kg 5-ALA prepared solution given orally, 3-5 hours before induction of anesthesia.\nRed light laser given by a Dye laser system, wave length of 635nm, in s dose of 150J/cm for 2000 seconds (33 minutes) will be given to tumor bed. In case of positive margins a second operation and 5-ALA administration or irradiation will be given.", 
            "intervention_name": "5-AMINOLEVULINIC ACID (5-ALA), is a non fluorescent prodrug.", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Aminolevulinic Acid"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 30, 2013", 
        "location": [
            {
                "contact": {
                    "email": "jacobb@tlvmc.gov.il", 
                    "last_name": "Jacob Bickels, MD/PhD", 
                    "phone": "+972-524266341"
                }, 
                "facility": {
                    "address": {
                        "city": "Tel Aviv", 
                        "country": "Israel", 
                        "zip": "64239"
                    }, 
                    "name": "The Aviv Sourasky Medical Center"
                }, 
                "investigator": {
                    "last_name": "Jacob Bickels, MD/PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "JACOBB@TLVMC.GOV.IL", 
                    "last_name": "Jacob Bickels, MD/PhD", 
                    "phone": "+972-524266341"
                }, 
                "facility": {
                    "address": {
                        "city": "Tel AVIV", 
                        "country": "Israel", 
                        "zip": "64239"
                    }, 
                    "name": "Tel Aviv sourasky medical center"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "1", 
        "official_title": "A PHASE 2, SINGLE CENTRE, SINGLE ARM STUDY TO DETERMINE THE EFFICACY AND SAFETY OF 5- ALA POHOTODYNAMIC THERAPY AS ADJUVANT THERAPY AFTER SURGICAL DISSECTION IN PATIENTS WITH DESMOID TUMORS.", 
        "overall_contact": {
            "email": "jACOBB@TLVMC.GOV.IL", 
            "last_name": "Jacob Bickels, MD/PhD", 
            "phone": "+972-524266341"
        }, 
        "overall_official": {
            "affiliation": "Tel-Aviv Sourasky Medical Center", 
            "last_name": "Jacob Bickels, MD/PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Ministry Of Health: Israel", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2023", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The primary endpoint is a binary variable where each patient is classified as a recurrence or a not recurrence case and will be determined by calculating the proportion of recurrence versus non recurrence rates", 
            "safety_issue": "Yes", 
            "time_frame": "three years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01898416"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Tel-Aviv Sourasky Medical Center", 
            "investigator_full_name": "michal roll", 
            "investigator_title": "Director research and development department", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "description": "Data from all subjects who receive any study drug will be included in the safety analyses. The severity of the toxicities will be graded according to the NCI CTCAE whenever possible. Adverse events will be summarized by worst NCI CTC grade. Adverse events classified as NCI CTCAE Grade 3 or Grade 4, study-drug-related events, and serious adverse events will be summarized separately. Laboratory data will be graded according to NCI CTCAE severity grade.", 
            "measure": "To assess the safety of study drug administration in the study population. To assess the 5 years local recurrence rate.", 
            "safety_issue": "Yes", 
            "time_frame": "five years"
        }, 
        "source": "Tel-Aviv Sourasky Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "michal roll", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}